Experimental drug aims to curb disinhibition in dementia patients
NCT ID NCT02534038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated early after enrolling only one person. Because of this, we have very little information about whether the drug works or is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AVP-786 (deuterated dextromethorphan/quinidine)
- What this could lead to
- If it works, this could point toward a treatment for disinhibition symptoms in people with brain diseases like Alzheimer's or frontotemporal dementia.
- What could go wrong
- This trial was terminated early with only 1 participant, so results are very limited. It is unclear if the drug is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada, 89106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your brain help unlock Alzheimer's secrets?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a gene therapy clear the toxic tau tangle in Alzheimer's?
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could a brain disease change behavior years before diagnosis?
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's